Best Practice & Research Clinical Haematology最新文献_第9页

Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA) 儿童、青少年和年轻人皮肤淋巴瘤和淋巴样细胞增生的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101448

Jamie Stokke , Annabelle Tann , Nader Kim El-Mallawany , Ilske Oschlies

{"title":"Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA)","authors":"Jamie Stokke , Annabelle Tann , Nader Kim El-Mallawany , Ilske Oschlies","doi":"10.1016/j.beha.2023.101448","DOIUrl":"10.1016/j.beha.2023.101448","url":null,"abstract":"<div><p>Cutaneous lymphomas and lymphoid proliferations (LPD) in children, adolescents, and young adults (CAYA) are a heterogeneous group of lymphoid neoplasms that present formidable diagnostic challenges to clinicians and pathologists alike. Although rare overall, cutaneous lymphomas/LPD occur in real-world settings and awareness of the differential diagnosis, potential complications, and various therapeutic approaches will help ensure the optimal diagnostic work-up and clinical management. Lymphomas/LPD involving the skin can occur as primary cutaneous disease in a patient that characteristically has lymphoma/LPD confined to the skin, or as secondary involvement in patients with systemic disease. This review will comprehensively summarize both primary cutaneous lymphomas/LPD that occur in the CAYA population as well as those CAYA systemic lymphomas/LPD with propensity for secondary cutaneous involvement. Focus on the most common primary entities occurring in CAYA will include lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma, and hydroa vacciniforme lymphoproliferative disorder.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"36 1","pages":"Article 101448"},"PeriodicalIF":2.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma 儿童、青少年和青年非霍奇金淋巴瘤的生物病理学

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101447

Megan S. Lim , Michelle Foley , Lara Mussolin , Reiner Siebert , Suzanne Turner

引用次数: 0

Principles of cost-effectiveness studies and their use in haematology 成本效益研究的原则及其在血液学中的应用

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101441

Isabelle Durand-Zaleski

引用次数: 1

Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults 儿童、青少年和年轻人淋巴母细胞淋巴瘤的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101449

William C. Temple , Stephanie Mueller , Michelle L. Hermiston , Birgit Burkhardt

引用次数: 1

Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults 儿童、青少年和年轻人实体器官移植后淋巴细胞增生性疾病的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101446

Jeremy Rubinstein , Keri Toner , Thomas Gross , Birte Wistinghausen

引用次数: 4

Diagnosis and management of rare paediatric Non-Hodgkin lymphoma 罕见儿童非霍奇金淋巴瘤的诊断和治疗

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI: 10.1016/j.beha.2023.101440

Ana C. Xavier , Ritsuro Suzuki , Andishe Attarbaschi

引用次数: 2

Improving clinical trials in higher-risk myelodysplastic syndromes 改善高危骨髓增生异常综合征的临床试验

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101406

Mikkael A. Sekeres

引用次数: 1

Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? 急性淋巴细胞白血病的CAR-T治疗是否应该与异体干细胞移植相结合?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101414

Alejandro Marinos, Helen E. Heslop

引用次数: 2

Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? 急性淋巴细胞白血病可测量残留病:多低才算足够低?

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/j.beha.2022.101407

Aaron C. Logan

{"title":"Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?","authors":"Aaron C. Logan","doi":"10.1016/j.beha.2022.101407","DOIUrl":"10.1016/j.beha.2022.101407","url":null,"abstract":"<div><p>Quantification of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) is a well-established clinical tool used to risk stratify patients during the course of chemotherapy, immunotherapy, and/or transplant therapy. As technologies evolve, the sensitivity for quantifying exceptionally low disease burden using either next generation sequencing (NGS) or next generation flow cytometry (NGF) has improved. It is now possible to detect MRD and quantify it precisely in patients who would previously have been deemed MRD negative by older, lower sensitivity methods. Persistence or recurrence of ALL disease burden above 10<sup>−4</sup> (0.01%) is accepted as the minimum threshold for making clinical decisions, but with NGS and NGF, clinicians now confront decision-making with disease burdens sometimes quantified to as low as 10<sup>−6</sup> (0.0001%, or one leukemia cell in a million leukocytes). Emerging data suggest these higher sensitivity methods are superior for identifying patients at lowest risk for relapse, but it remains controversial whether to institute therapies such as blinatumomab or chimeric antigen receptor (CAR)-T cells or move patients to allogeneic hematopoietic cell transplant (alloHCT) when they have quantifiable disease burden less than 10<sup>−4</sup>. With additional evidence to facilitate integration of highly sensitive MRD quantification into clinical care and to contextualize MRD within the genotype of individual patients, it will likely be increasingly possible to identify patients able to avoid alloHCT and potentially even de-escalate therapy.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"35 4","pages":"Article 101407"},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692622000627/pdfft?md5=3eedb7a2c99ca8220459819175d732fb&pid=1-s2.0-S1521692622000627-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10473776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Editorial Board / Aims & Scope 编辑委员会/目标与范围

IF 2.1 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2022-12-01 DOI: 10.1016/S1521-6926(22)00087-1

引用次数: 0